

Supporting Information

Solid-Phase Polyamine Synthesis Using Piperazine and Piperidine Building Blocks

Christian A. Olsen,[†] Matthias Witt,[‡] Jerzy W. Jaroszewski,[†] and Henrik Franzyk[†]

General Methods

Unless otherwise stated, starting materials were obtained from commercial suppliers. (*S*)-*O*-(*tert*-Butyl)tyrosine and trityl resins (100-200 mesh, 1% DVB) were obtained from Novabiochem (Läufelingen, Switzerland). Tetrahydrofuran (THF) was distilled under N₂ from sodium/benzophenone immediately before use. Dry dichloromethane was distilled from P₂O₅ and kept over 4 Å molecular sieves. Water for reversed-phase high-performance liquid chromatography (HPLC) was filtered through a 0.22 µm pore filter. ¹H NMR and ¹³C NMR spectra were recorded at 400.14 MHz and 100.62 MHz, respectively, on a Bruker Avance 400 spectrometer, or at 600.13 and 150.92 MHz, respectively, on a Bruker Avance 600 spectrometer, using CDCl₃ or CD₃OD as solvent and TMS as internal standard. Coupling constants (*J* values) are given in hertz (Hz), and multiplicities of ¹H NMR signals are reported as follows: s, singlet; d, doublet; t, triplet; m, multiplet; br, broad signal, and signals corresponding to the minor rotamers of the final products are marked with an asterisk (*). Vacuum liquid chromatography (VLC) was performed using Merck silica gel 60H, particle size < 45 µm (90%). Preparative HPLC system consisted of a Waters model 590 pump, a Waters Lambda-Max model 481 spectrophotometric detector and a 25 × 2.12 cm Phenomenex Luna 5 C18(2) column, 5 µm. The chromatograph operated isocratically at a flow-rate of 14 mL/min, using water/acetonitrile/TFA 82:18:0.1 as mobile phase. High-resolution mass (HRMS) measurements for exact mass determination were performed on a Bruker APEX III Fourier transform mass spectrometer equipped with a 7 tesla superconducting magnet and the external electrospray ion source (Apollo source). The spectra were externally calibrated with a capillary skimmer dissociation spectrum of LHRH (luteinizing hormone releasing hormone). The samples were introduced into the electrospray ion source using a 250 µL syringe, with a syringe pump flow 2 µL/min.

N-Teoc-4-[*O*-(2-nitrobenzenesulphonyl)ethanol]piperidine (7)

2-(4-Piperidyl)ethanol (1.176 g, 9.10 mmol) was dissolved in MeOH (15 mL) and 2-trimethylsilyl ethyl *p*-nitrophenylcarbonate (2.60 g, 9.10 mmol) in CH₂Cl₂ (15 mL) was added and the mixture was stirred at room temperature for 16 h. The methanol was removed in vacuo and EtOAc (10 mL) was added. The organic phase was washed with water (4 × 100 mL) and brine (2 × 10 mL), dried (Na₂SO₄), filtered, concentrated and dried in

vacuo. This gave 2.15 g (87%) of the crude product as a yellow syrup. The crude product (2.09 g, 7.64 mmol) was dissolved in CH_2Cl_2 (20 mL) and treated with TEA (2.65 mL, 19.1 mmol, 2.5 eq) and NsCl (4.23 g, 19.1 mmol, 2.5 eq) in CH_2Cl_2 (10 mL). After stirring for 0.5 h at 0°C and 2 h at room temperature, the mixture was concentrated and the residue was loaded onto a VLC-column (6×6 cm). Elution with hexane/EtOAc (10:1, 6:1, 5:1 and 4:1) afforded 2.90 g (82%) of **7** as a colourless syrup. ^1H NMR (600 MHz, CDCl_3): δ 8.13 (ddd, $J = 7.8$ Hz, $J = 1.4$ Hz, $J = 0.4$ Hz, 2H), 7.84-7.75 (m, 3H), 4.34 (t, $J = 6.0$ Hz, 2H), 4.17-4.10 (m, 4H), 2.70 (br s, 2H), 1.71-1.64 (m, 5H), 1.09 (m, 2H), 0.99 (m, 2H), 0.03 (br s, 9H). ^{13}C NMR (150 MHz, CDCl_3): δ 155.5, 148.5, 134.9, 132.2, 131.3, 129.5, 124.8, 69.9, 63.4, 43.8 (2 C), 35.3 (2 C), 32.1, 31.6, 17.8, -1.4 (3 C). HRMS: $\text{C}_{19}\text{H}_{30}\text{N}_2\text{O}_7\text{SSiNa}$ requires MNA^+ at m/z 481.14352; found, 481.14333 (ΔM : 0.42 ppm).

***N*-Aminoethyl-*N'*-Teoc piperazine (**8**)**

N-(2-Aminoethyl)piperazine (0.50 mL, 3.81 mmol) was dissolved in MeOH (25 mL) and stirred at -50°C under N_2 . Ethyl trifluoroacetate (0.50 mL, 4.19 mmol, 1.1 eq) in MeOH (2 mL) was added dropwise during 0.5 h, the temperature was allowed to reach 0°C , and the mixture was stirred for additional 0.5 h. A solution of 2-trimethylsilyl ethyl *p*-nitrophenyl carbonate (1.41 g, 4.95 mmol, 1.3 eq) in CH_2Cl_2 (10 mL) was added and the mixture was stirred for 16 h at room temperature. Water (2 mL) and concentrated NaOH (2 mL) were added and stirring was continued for 3 h. The methanol was removed in vacuo and EtOAc (150 mL) was added. The organic phase was washed with water (4×100 mL) and brine (2×100 mL), dried (Na_2SO_4), filtered, concentrated and dried in vacuo. The crude product was loaded directly onto a trityl chloride resin. ^{13}C NMR (100 MHz, CDCl_3): δ 155.6, 63.5, 60.7 (2 C), 53.0 (2 C), 43.6, 38.5, 17.7, -1.4 (3 C).

Preparation of Resin 9

Trityl chloride resin (160 mg, 0.216 mmol) was suspended in CH_2Cl_2 (2 mL), compound **8** (300 mg, 1.10 mmol, 5 eq) in CH_2Cl_2 (2 mL) was added and the resin was shaken for 16 h. The resin was then drained, washed with CH_2Cl_2 , DMF and CH_2Cl_2 (3×5 mL of each), and treated with $\text{Bu}_4\text{NF} \cdot 3 \text{H}_2\text{O}$ (341 mg, 1.10 mmol, 5 eq) in DMF (3 mL) for 2 h. Washing with CH_2Cl_2 , DMF and CH_2Cl_2 (3×5 mL of each) and drying in vacuo afforded resin **9**.

Compound 2

Solid-Phase Sulphonate Coupling and Removal of the Teoc Group

Compound **7** (297 mg, 0.648 mmol, 3 eq) in THF (2 mL) and DIEA (113 μL , 0.648, 3 eq) were added to the resin **9** (0.216 mmol) suspended in CH_2Cl_2 (2 mL) and the mixture was shaken at 50°C for 16 h. After cooling to room temperature the resin was drained and washed with CH_2Cl_2 , DMF and CH_2Cl_2 (3×5 mL of each). The Teoc group was then removed by treatment with $\text{Bu}_4\text{NF} \cdot 3 \text{H}_2\text{O}$ (341 mg, 1.10 mmol, 5 eq) in DMF (2 mL) for 30 min at 50°C . Washing with CH_2Cl_2 , DMF and CH_2Cl_2 (3×5 mL of each) followed by drying in vacuo gave resin **10**.

Attachment of Tyrosine and Butyryl Residues

Resin **10** was suspended in DMF (1 mL). DIEA (98 μ L, 0.56 mmol, 2.6 eq), HODhbt (35 mg, 0.216 mmol, 1 eq) in DMF (1 mL) and (S)-Fmoc-Tyr(Bu^t)-OPfp (405 mg, 0.648 mmol, 3 eq) in DMF (2 mL) were added successively and the mixture was shaken at room temperature under N₂ for 5 h. The resulting resin was treated with piperidine in DMF (20% v/v, 2 mL) for 10 min at room temperature, and washed with DMF (3 \times 5 mL), then treated with piperidine in DMF (20% v/v, 2 mL) for 10 min again, and washed with DMF, CH₂Cl₂ and DMF (3 \times 5 mL each). After removal of the Fmoc group the resin was suspended in DMF (1 mL) and DIEA (98 μ L, 0.56 mmol, 2.6 eq), HODhbt (35 mg, 0.216 mmol, 1 eq) in DMF (1 mL) and butanoic acid Pfp ester (165 mg, 0.648 mmol, 3 eq) in DMF (2 mL) were added successively. The resulting mixture was shaken at room temperature under N₂ for 16 h. The resin was drained and washed with CH₂Cl₂, DMF and CH₂Cl₂ (3 \times 5 mL of each) to give resin **11**.

Deprotection and Cleavage from the Resin

The resin was treated with CH₂Cl₂-TFA (50:50, v/v; 3 mL) at room temperature for 1 h. The drained solvent was combined with washings [MeOH (2 \times 5 mL) and CH₂Cl₂ (2 \times 5 mL)], evaporated in vacuo and purified by RP-18 VLC (H₂O-MeCN-TFA (95:5:0.1, 90:10:0.1, 85:15:0.1 and 80:20:0.1), followed by reversed phase HPLC [H₂O-MeCN-TFA (82:18:0.1)] to give 50 mg (28%) of the final product (**2**) as a clear syrup. ¹H NMR (400 MHz, CD₃OD): δ 7.06/7.01* (each, d, J = 8.4 Hz, 2 H, Ar-H), 6.73/6.69* (each, d, J = 8.4 Hz, 2 H, Ar-H), 4.98 (m, 1 H, H- α), 4.44 (br d, J = 12.3 Hz, 1 H, CH₂NCO_{eq1}), 3.96/3.93* (each, br d, J = 12.7 Hz, 1 H, CH₂NCO_{eq2}), 3.67-2.38 (20 H), 2.17/2.15* (t, J = 7.5 Hz, 2 H, CH₂CO), 1.71-1.08 (7 H), 1.60/1.58* (m, 2 H, CH₂CH₂CO), 0.91/0.88* (t, J = 7.5 Hz, 3 H, CH₃). ¹³C NMR (100 MHz, CD₃OD): δ 175.5 (CO), 171.8 (CO), 157.6*/157.5 (Ar-C_{para}), 131.9/131.4* (2 C), 128.9/128.8* (Ar-C_{ipso}), 116.6/116.2* (2 C), 55.8*/55.7 (CH₂N(CH₂)₂), 54.5 (CH₂N(CH₂)₂), 53.0 (2 C), 51.8*/51.4 (C- α), 50.6 (2 C), 47.1*/46.8 (CH₂NCO), 43.4/43.3* (CH₂NCO), 39.0*/38.6 (C- β), 38.5 (CH₂CO), 37.3 (CH₂NH₂), 34.9*/34.4 (CH), 33.1*/32.3, 32.4*/32.3, 31.0, 20.2 (CH₂CH₃), 13.9 (CH₃). ESI-MS: 474.4 (M + 1). HRMS: C₂₆H₄₄N₅O₃ requires M + 1 at m/z 474.34387; found, 474.34373 (Δ M: 0.30 ppm).

Compound 3

Piperazine bound to trityl resin was treated as described above for **2**. The crude was purified by RP-18 VLC (H₂O-MeCN-TFA (95:5:0.1, 90:10:0.1, 85:15:0.1 and 80:20:0.1), followed by reversed phase HPLC [H₂O-MeCN-TFA (82:18:0.1)] to give 50 mg (60%) of the final product (**3**) as a clear syrup. ¹H NMR (400 MHz, CD₃OD): δ 7.06/7.01* (each, d, J = 8.4 Hz, 2 H, Ar-H), 6.75/6.69* (each, d, J = 8.4 Hz, 2 H, Ar-H), 4.98 (m, 1 H, H- α), 4.43 (br d, J = 12.3 Hz, 1 H, CH₂NCO_{eq1}), 3.91/3.89* (2 br d, J = 12.7 Hz, 1 H, CH₂NCO_{eq2}), 3.48-3.30 (8 H), 3.13-2.78 (6 H), 2.59*/2.50 (each, br t, J = 12.3 Hz, J = 12.7 Hz, 2 H, CH₂NCO_{ax}), 2.18/2.15* (each, t, J = 7.4 Hz, 2 H, CH₂CO), 1.71-1.08 (7 H), 1.60/1.58* (m, 2 H, CH₂CH₂CO), 0.91/0.88* (each, t, J = 7.4 Hz, 3 H, CH₃). ¹³C NMR (100 MHz, CD₃OD): δ 175.5 (CO), 171.8 (CO), 157.6*/157.5 (Ar-C_{para}), 131.9/131.4* (2 C), 128.8/128.7* (Ar-C_{ipso}), 116.6/116.2* (2 C), 56.1*/56.0 (CH₂N(CH₂)₂), 51.8*/51.4 (C- α), 50.0 (2 C), 47.1*/46.9 (CH₂NCO), 43.5/43.4* (CH₂NCO), 42.8 (2 C), 39.0*/38.6 (C- β), 38.5 (CH₂CO), 34.9*/34.4 (CH), 33.3*/32.4, 32.5*/32.3, 31.7, 20.2 (CH₂CH₃), 13.9 (CH₃). HRMS: C₂₄H₃₉N₄O₃ requires M + 1 at m/z 431.30167 found, 431.30161 (Δ M: 0.14 ppm).

Compound 4

Solid-Phase Sulphonate Coupling and Removal of the Teoc Group


Compound **7** (205 mg, 0.446 mmol, 3 eq) in THF (2 mL) and DIEA (78 μ L, 0.446, 3 eq) were added to trityl resin bound piperazine (0.149 mmol) suspended in toluene (2 mL) and shaken at 50°C for 16 h. After cooling to room temperature the resin was washed with CH_2Cl_2 , DMF and CH_2Cl_2 (3×5 mL of each), and the procedure was repeated, shaking for 2 h. The Teoc group was then removed by treatment with $\text{Bu}_4\text{NF} \cdot 3 \text{H}_2\text{O}$ (235 mg, 0.745 mmol, 5 eq) in DMF (2 mL) for 30 min at 50°C. Washing with CH_2Cl_2 , DMF and CH_2Cl_2 (3×5 mL of each) followed by drying in vacuo gave resin **12**. Coupling and Teoc removal as described above was repeated to give resin **13**.

Attachment of Tyrosine and Butyryl Residues

Resin **13** was suspended in DMF (1 mL). DIEA (67 μ L, 0.387 mmol, 2.6 eq), HODhbt (24 mg, 0.149 mmol, 1 eq) in DMF (1 mL) and (S)-Fmoc-Tyr(Bu^t)-OPfp (279 mg, 0.446 mmol, 3 eq) in DMF (2 mL) were added successively and the mixture was shaken at room temperature under N_2 for 3 h. The resulting resin was treated with piperidine in DMF (20% v/v, 2 mL) for 10 min at room temperature, and washed with DMF (3×5 mL), then treated with piperidine in DMF (20% v/v, 2 mL) for 10 min again, and washed with DMF, CH_2Cl_2 and DMF (3×5 mL each). After removal of the Fmoc group the resin was suspended in DMF (1 mL) and DIEA (67 μ L, 0.387 mmol, 2.6 eq), HODhbt (24 mg, 0.149 mmol, 1 eq) in DMF (1 mL) and butanoic acid Pfp ester (113 mg, 0.446 mmol, 3 eq) in DMF (2 mL) were added successively. The resulting mixture was shaken at room temperature under N_2 for 16 h. The resin was drained and washed with CH_2Cl_2 , DMF and CH_2Cl_2 (3×5 mL of each) to give resin **14**.

Deprotection and Cleavage from the Resin

Resin **14** was treated with CH_2Cl_2 -TFA (50:50, v/v; 3 mL) at room temperature for 1 h. The drained solvent was combined with washings [MeOH (2×5 mL) and CH_2Cl_2 (2×5 mL)], evaporated in vacuo and purified by RP-18 VLC (H_2O -MeCN-TFA (95:5:0.1, 90:10:0.1, 85:15:0.1 and 80:20:0.1), followed by reversed phase HPLC [H_2O -MeCN-TFA (82:18:0.1)] to give 34 mg (26%) of the final product (**4**) as a clear syrup. ^1H NMR (400 MHz, CD_3OD): δ 7.07/7.01* (each, d, $J = 8.4$ Hz, 2 H, Ar-H), 6.73/6.69* (each, d, $J = 8.4$ Hz, 2 H, Ar-H), 4.99 (m, 1 H, H- α), 4.44 (br d, $J = 12.3$ Hz, 1 H, $\text{CH}_2\text{NCO}_{\text{eq1}}$), 3.92/3.89* (each, br d, $J = 12.7$ Hz, 1 H, $\text{CH}_2\text{NCO}_{\text{eq2}}$), 3.57 (br s, 8 H), 3.30-2.78 (10 H), 2.59*/2.50 (each, br t, $J = 12.3$ Hz, $J = 12.7$ Hz, 2 H, $\text{CH}_2\text{NCO}_{\text{ax}}$), 2.18/2.15* (each, t, $J = 7.3$ Hz, 2 H, CH_2CO), 2.09-1.12 (14 H), 1.62/1.59* (m, 2 H, $\text{CH}_2\text{CH}_2\text{CO}$), 0.91/0.89* (each, t, $J = 7.3$ Hz, 3 H, CH_3). ^{13}C NMR (100 MHz, CD_3OD): δ 175.6 (CO), 171.8 (CO), 157.5 (Ar-C_{para}), 131.1/130.6* (2 C), 128.8/128.7* (Ar-C_{ipso}), 116.6/116.2* (2 C), 56.2/56.0*, 55.8, 53.9*/53.7, 53.6, 51.8*/51.4 (C- α), 49.8 (2 C), 47.1/46.8* (CH_2NCO), 43.4/43.3* (CH_2NCO), 42.3/42.1* (2 C), 39.0*/38.6 (C- β), 38.5 (CH_2CO), 34.9/34.8* (CH), 34.5/34.3* (CH), 33.1 (CH_2), 32.4*/32.3 (CH_2), 32.1 (CH_2), 31.2*/31.1 (CH_2), 30.3 (2 C), 20.2 (CH_2CH_3), 13.9 (CH_3). ESI-MS: 542.5 (M + 1). HRMS: $\text{C}_{31}\text{H}_{52}\text{N}_5\text{O}_3$ requires M + 1 at m/z 542.40647; found, 542.40640 (Δ M: 0.13 ppm).




Current Data Parameters
NAME cao.010403
EXPNO 3
PROCNO 1


F2 - Acquisition Parameters
Date_ 20030401
Time 15.21
INSTRUM av400
PROBHD 5 mm QNP 1H-13
PULPROG zg30
TD 32768
SOLVENT MeOD
NS 16
DS 0
SWH 8250.825 Hz
FIDRES 0.251795 Hz
AQ 1.9858514 sec
RG 128
DW 60.600 usec
DE 6.00 usec
TE 300.0 K
D1 1.00000000 sec

===== CHANNEL f1 =====
NUC1 1H
P1 10.50 usec
PL1 -6.00 dB
SF01 400.1324710 MHz

F2 - Processing parameters
SI 131072
SF 400.1315840 MHz
WDW EM
SSB 0
LB 0.10 Hz
GB 0
PC 1.00

1D NMR plot parameters
CX 20.00 cm
CY 20.00 cm
FIP 9.000 ppm
F1 3601.18 Hz
F2P -1.000 ppm
F2 -400.13 Hz
PPMCM 0.50000 ppm/cm
HZCM 200.06580 Hz/cm






Current Data Parameters
 NAME cao.110803
 EXPNO 1
 PROCNO 1


F2 - Acquisition Parameters
 Date_ 20030811
 Time 11.23
 INSTRUM av400
 PROBHD 5 mm DUL 1H-13
 PULPROG zg30
 TD 32768
 SOLVENT MeOD
 NS 16
 DS 0
 SWH 8250.825 Hz
 FIDRES 0.251795 Hz
 AQ 1.9858514 sec
 RG 128
 DW 50.600 usec
 DE 6.00 usec
 TE 300.0 K
 D1 1.00000000 sec

===== CHANNEL f1 =====
 NUC1 1H
 P1 10.50 usec
 PL1 -6.00 dB
 SF01 400.1324710 MHz

F2 - Processing parameters
 SI 131072
 SF 400.1309620 MHz
 WDW EM
 SSB 0
 LB 0.10 Hz
 GB 0
 PC 1.00

1D NMR plot parameters
 CX 20.00 cm
 CY 20.00 cm
 F1P 9.000 ppm
 F1 3601.18 Hz
 F2P -1.000 ppm
 F2 -400.13 Hz
 PPMM 0.50000 ppm/cm
 HZCM 200.05549 Hz/cm






Current Data Parameters
 NAME cao.070703
 EXPNO 4
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20030707
 Time 12.26
 INSTRUM av400
 PROBHD 5 mm DUL 1H-13
 PULPROG zg30
 TD 32768
 SOLVENT MeOD
 NS 32
 DS 0
 SWH 8250.825 Hz
 FIDRES 0.251795 Hz
 AQ 1.9858514 sec
 RG 128
 DW 60.600 usec
 DE 6.00 usec
 TE 300.0 K
 D1 1.00000000 sec

===== CHANNEL f1 =====
 NUC1 1H
 P1 10.50 usec
 PL1 -6.00 dB
 SF01 400.1324710 MHz

F2 - Processing parameters
 SI 131072
 SF 400.1315838 MHz
 WDW EM
 SSB 0
 LB 0.10 Hz
 GB 0
 PC 1.00

1D NMR plot parameters
 CX 20.00 cm
 CY 12.00 cm
 FIP 9.000 ppm
 F1 3601.18 Hz
 F2P -1.000 ppm
 F2 -400.13 Hz
 PPMCM 0.50000 ppm/cm
 HZCM 200.06580 Hz/cm




Compound Chromatogram Report - MS

Analysis Name: jol.d **Instrument:** LC-MSD-Trap_00074 **Print Date:** 07/11/03 10:06:28
Method: Copy of peptid1.MS **Operator:** NAJ **Acq. Date:** 11-07-03 09:53:45
Sample Name: XXXXXXXXXX
Analysis Info:

Acquisition Parameter:

Mass Range Mode	Std/Normal	Trap Drive	44.6	Scan Begin	50 m/z
Ion Polarity	Positive	Skim 1	59.2 Volt	Scan End	1000 m/z
Ion Source Type	ESI	Skim 2	6.0 Volt	Averages	5 Spectra
Dry Temp (Set)	350 °C	Octopole RF Amplitude	120.0 Vpp	Max. Accu Time	50000 µs
Nebulizer (Set)	15.00 psi	Capillary Exit	146.0 Volt	ICC Target	20000
Dry Gas (Set)	4.00 l/min	Cap Exit Offset	86.8 Volt	Charge Control	on




Compound Chromatogram Report - MS

Analysis Name: jol.d
Method: Copy of peptid1.MS
Sample Name: CAO 2-38
Analysis Info:

Instrument: LC-MSD-Trap_00074
Operator: NAJ
Print Date: 07/11/03 10:21:32
Acq. Date: 11-07-03 09:53:45

Acquisition Parameter:

Mass Range Mode	Std/Normal	Trap Drive	44.6	Scan Begin	50 m/z
Ion Polarity	Positive	Skim 1	59.2 Volt	Scan End	1000 m/z
Ion Source Type	ESI	Skim 2	6.0 Volt	Averages	5 Spectra
Dry Temp (Set)	350 °C	Octopole RF Amplitude	120.0 Vpp	Max. Accu Time	50000 µs
Nebulizer (Set)	15.00 psi	Capillary Exit	146.0 Volt	ICC Target	20000
Dry Gas (Set)	4.00 l/min	Cap Exit Offset	86.8 Volt	Charge Control	on



Sample CAO 2.38



474.34373

Chemical formula $[M+H]^+$: $[C_{26}H_{44}N_5O_3]^+$


theory: 474.34387

experiment: 474.34373

ΔM : 0.30 ppm



Sample CAO 2.06



Sample CAO 2.53

